Otsuka Of Japan Joins Other MNCs And Considers R&D Investment Deal With Korean Ministry
This article was originally published in PharmAsia News
Executive Summary
Japan's Otsuka Pharmaceutical is considering signing a memorandum of understating regarding a research and development investment deal with the Korean Ministry of Health, Welfare and Family Affairs, the Korean agency disclosed May 29. Currently, Novartis Korea is in the process of signing a MOU in investing $100 million in R&D with the ministry, and Korean subsidiaries of AstraZeneca and Pfizer have signed the MOUs. Besides Ostuka, Sanofi-Aventis is also considering a similar investment. Korea requires a minimum of $100 million in such R&D investment deals. (Click here for more - Japanese language